EP Wealth Advisors LLC Has $3.85 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

EP Wealth Advisors LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,466 shares of the biopharmaceutical company’s stock after acquiring an additional 356 shares during the quarter. EP Wealth Advisors LLC’s holdings in Gilead Sciences were worth $3,845,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Tompkins Financial Corp boosted its stake in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the last quarter. Fortitude Family Office LLC purchased a new stake in Gilead Sciences in the 4th quarter valued at $29,000. Private Wealth Management Group LLC purchased a new position in Gilead Sciences during the 4th quarter worth $29,000. Sachetta LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at about $30,000. Finally, Rakuten Securities Inc. purchased a new position in Gilead Sciences during the fourth quarter worth about $33,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

NASDAQ:GILD traded up $2.24 during midday trading on Friday, hitting $65.06. The company had a trading volume of 9,793,590 shares, compared to its average volume of 6,402,712. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The stock’s fifty day moving average price is $66.03 and its 200-day moving average price is $73.33. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The company has a market capitalization of $81.06 billion, a PE ratio of 180.72, a P/E/G ratio of 1.30 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the business earned $1.37 earnings per share. As a group, research analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.73%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GILD. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a research report on Wednesday, April 24th. Maxim Group lowered their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Mizuho decreased their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Finally, UBS Group dropped their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $83.69.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.